secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001104659-22-091225
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx reports Q2 2022 net loss of $2.6M; Phase 2b trial enrollment continues with site expansion
--------------------------------------------------------------------------------

- Net loss $2.6M ($0.26/diluted) for Q2 2022 vs $4.0M ($0.57) a year ago.
- Cash $9.1M at June 30, 2022, down from $13.1M at Dec 31, 2021.
- Phase 2b CDI trial enrollment slower; up to 30 clinical sites being added.
- Raised $4.225M via July 2022 direct offering to institutional investor and executives.
- Ibezapolstat showed favorable killing kinetics vs vancomycin in lab studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922091225/0001104659-22-091225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922091225/tm2223469d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-091225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer